Corcept Therapeutics (CORT) Total Current Liabilities (2010 - 2026)

Corcept Therapeutics has disclosed Total Current Liabilities across 17 years of filings, most recently posting $149.2 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $149.2 million, up 4.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $149.2 million (up 4.28% YoY), and the FY2025 annual result was $166.1 million, up 17.98% from the prior year.
• Total Current Liabilities came in at $149.2 million for Q1 2026 at Corcept Therapeutics, down from $166.1 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $172.3 million in Q3 2025 to a low of $49.1 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $104.5 million (2023), against an average of $110.0 million.
• Across the five-year window, Total Current Liabilities jumped 129.65% in 2023 and advanced 3.56% in 2024, its largest moves.
• Corcept Therapeutics' Total Current Liabilities stood at $72.5 million in 2022, then soared by 44.16% to $104.5 million in 2023, then jumped by 34.7% to $140.8 million in 2024, then advanced by 17.98% to $166.1 million in 2025, then declined by 10.18% to $149.2 million in 2026.
• The last three Total Current Liabilities figures came in at $149.2 million (Q1 2026), $166.1 million (Q4 2025), and $172.3 million (Q3 2025), per Business Quant data.